CoChat

Phase I Trial of MS-275, a Histone Deacetylase Inhibitor, Administered Weekly in Refractory Solid Tumors and Lymphoid Malignancies

Open access
Kummar, Shivaani, Gutierrez, Martin, Gardner, Erin R., Donovan, Erin, Hwang, Kyunghwa, Chung, Eun Joo, Lee, Min-Jung, Maynard, Kim, Kalnitskiy, Mikhail, Chen, Alice, Melillo, Giovanni, Ryan, Qin C., Conley, Barbara, Figg, William D., Trepel, Jane B., Zwiebel, James, Doroshow, James H., Murgo, Anthony J. · 2007 · Clinical Cancer Research
Cited by 131

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Purpose: MS-275 is a histone deacetylase inhibitor that has shown potent and unique anticancer activity in preclinical models. The aims of this phase I trial were to determine the dose-limiting toxicities and maximum tolerated dose of oral MS-275 in humans administered with food on a once weekly schedule and to study the pharmacokinetics of oral MS-275. Experimental Design: Patients with refractory solid tumors and lymphoid malignancies were treated with oral MS-275 on a once weekly schedule for 4 weeks of a 6-week cycle. Samples for pharmacokinetic and pharmacodynamic analyses were collected during cycle 1. Protein acetylation in subpopulations of peripheral blood mononuclear cells was measured using a multivariable flow cytometry assay. Results: A total of 22 patients were enrolled, and 19 were considered evaluable for toxicity. The maximum tolerated dose was 6 mg/m2. No National Cancer Institute Common Toxicity Criteria grade 4 toxicities were observed. Dose-limiting grade 3 toxicities were reversible and consisted of hypophosphatemia, hyponatremia, and hypoalbuminemia. Non–dose-limiting grade 3 myelosuppression was also observed. The mean terminal half-life of MS-275 was 33.9 ± 26.2 and the Tmax ranged from 0.5 to 24 h. Although there was considerable interpatient variability in pharmacokinetics, the area under the plasma concentration versus time curve increased linearly with dose. Conclusions: MS-275 is well tolerated at a dose of 6 mg/m2 administered weekly with food for 4 weeks every 6 weeks. Drug exposure increases linearly with dose, and protein acetylation increased in all the subpopulations of peripheral blood mononuclear cells following MS-275 administration.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-07-0791

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 131

Metadata

Authors
Kummar, S., Gutierrez, M., Gardner, E. R., Donovan, E., Hwang, K., Chung, E. J., Lee, M.-J., Maynard, K., Kalnitskiy, M., Chen, A., Melillo, G., Ryan, Q. C., Conley, B., Figg, W. D., Trepel, J. B., Zwiebel, J., Doroshow, J. H., & Murgo, A. J.
Venue
Clinical Cancer Research
Published
2007-09-15
Volume
13
Issue
18
Pages
5411-5417
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2063819389
Cited by
131
References
3
FWCI
4.79
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase I Trial of MS-275, a Histone Deacetylase Inhibitor, Administered Weekly in Refractory Solid Tumors and Lymphoid Malignancies. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-07-0791
The paper
Kummar, S., Gutierrez, M., Gardner, E. R., Donovan, E., Hwang, K., Chung, E. J., Lee, M.-J., Maynard, K., Kalnitskiy, M., Chen, A., Melillo, G., Ryan, Q. C., Conley, B., Figg, W. D., Trepel, J. B., Zwiebel, J., Doroshow, J. H., & Murgo, A. J. (2007). Phase I Trial of MS-275, a Histone Deacetylase Inhibitor, Administered Weekly in Refractory Solid Tumors and Lymphoid Malignancies. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-07-0791

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.